Table 1. General Characteristics of Patients from Nine Clinical Trials Included in the Meta-Analysis a.
| Reference | Year | Press | Collect Date | Long-Term Follow up | Type of Treatment | Number of Patient | Non-SVR | SVR | HCC | Death |
|---|---|---|---|---|---|---|---|---|---|---|
| Cardoso et al. (15) | 2010 | Journal of Hepatology | 1987 - 2007 | Median 35 year | Peg-IFN + RBV, Peg-IFN, Interferon with or without RBV | 307 | 204 | 103 | SVR: 6, Non-SVR: 40 | SVR: 6, Non-SVR: 40 |
| Maruoka et al. (16) | 2012 | Journal of Gastroenterology and Hepatology | 1986 - 2005 | 9.9 ± 5.3 years | IFN with or without RBV | 577 | 356 | 221 | SVR: 5, Non-SVR: 80 | SVR: 10, Non-SVR: 74 |
| Backus et al. (17) | 2011 | Clinical of Gastroenterology and Hepatology | 2001 - 2007 | Approximately 3.8 years | Peg-IFN + RBV | GT1:12166, GT2:2904, GT3:1794 | GT1:7918, GT2:815, GT3:697 | GT1:4248, GT2:2089, GT3:1097 | SVR: 223, Non-SVR: 283 | SVR: 525, Non-SVR: 1440 |
| Iacobellis et al. (18) | 2011 | Clinical of Gastroenterology and Hepatology | 2002 - 2006 | 51 ± 18 months | Peg-IFN + RBV | 75 | 51 | 24 | SVR: 5, Non-SVR: 11 | SVR: 2, Non-SVR: 23 |
| Alfaleh et al. (19) | 2013 | Liver international | 2001 - 2012 | 63.8 ± 32.8 months | Peg-IFN with or without RBV | 157 | 95 | 62 | SVR: 0, Non-SVR: 4 | SVR: 0, Non-SVR: 8 |
| Di Martino et al. (20) | 2011 | Journal of viral hepatitis | 1994 - 2001 | Median 59 months | All | 368 | 125 | 59 | SVR: 1, Non-SVR: 8 | SVR: 0, Non-SVR: 9 |
| Morgan et al. (21) | 2010 | Hepatology | 2000 - 2003 | Median 3.5 years | Peg-IFN + RBV | 1145 | 386 | 140 | SVR: 2, Non-SVR: 33 | SVR: 4, Non-SVR: 75 |
| Yamasaki et al. (22) | 2012 | BMC Gastroenterology | 1992 - 2011 | Median 11.5 years | IFN with or without RBV | 351 | 80 | 72 | None | SVR: 9, Non-SVR: 16 |
| Wang et al. (23) | 2013 | Hepatology International | None | Median 8 years | Peg-IFN + RBV | 138 | 27 | 111 | SVR: 15, Non-SVR: 6 | None |
a Abbreviations: HCC, hepatocellular carcinoma; and SVR, sustain virologic response.